Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodality therapy with or without adjuvant durvalumab in muscle-invasive bladder cancer
2019-001310-42Phase 2Active
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Disease-free survival. Started Jul 2019; status: active.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2019-001310-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001310-42.